Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

operations through 2010 based on current expense projections.

Preclinical / Research

-- Publication of data supporting Sangamo's first ZFN Therapeutic program for the treatment of HIV/AIDS in high-impact journal Nature Biotechnology demonstrating highly efficient and specific ZFN-modification of CCR5 in human T-cells resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection (Perez et al., 2008, Nat Biotechnol.,26: 808).

-- Nature Biotechnology publication establishing the utility of ZFNs in the generation of transgenic animals and the potential broadening of the production of knockout transgenic models beyond mouse models (Doyon et al., 2008, Nat. Biotechnol. 26: 702).

-- Publication of data in the journal Proceedings of the National Academy of Sciences (PNAS) establishing Sangamo's ZFN technology as a new approach for rapid generation of "knock-out" cell lines (Santiago et al., 2008, PNAS 105: 5809).

Select 2009 Objectives

During the briefing Sangamo will also discuss the following objectives for 2009:

-- Sangamo expects to file an IND for SB-313 to evaluate the drug in a Phase 1 trial in subjects with glioblastoma.

-- The company expects to present data from its three ongoing Phase 2 clinical trials of SB-509 in subjects with DN, SB-509-601 in subjects with mild to moderate DN, SB-509-701 subjects with moderate to severe DN with a blocked nerve and SB-509-703 in stem cell mobilization.

-- Establishment of a strategic partnership for SB-509.

-- Sangamo estimates that it expects to end 2009 with approximately $40M in cash and cash equivalents, based on current expense projections and expected progress in existing corporate relationships.

The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website and is a
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... -- Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... Healthcare Conference on Wednesday, September 10. ... will provide an update on the company, beginning at ... Time).   A webcast of the presentation ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... methods developed to prevent and eradicate the prevalence of ... methods are confined to low specificity, safety and large ... look for a better solution. It has been discovered ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... effectiveness for, patients, but Gilead Sciences and Merck and Co. ... ... LOS ANGELES, Sept. 10 AIDS Healthcare,Foundation (AHF) today called ... three-in-one, once daily lifesaving HIV,treatment, Atripla, in developing countries. When ...
... BioMosaics Inc., a cancer,biomarker development company, announced today ... products for the identification of Glypican-3,(GPC3) in human ... tests. This will,allow the GPC3 (Human Glypican-3) ELISA ... and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone,1G12) ...
Cached Medicine Technology:Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 2Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 3BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe 2
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/1/2014)... NAPW honors ... Orthopedics Pain Treatment & Cardiology, as a ... is recognized with this prestigious distinction for leadership ... organization of women in the country, spanning virtually ... Professional Women is a powerfully vibrant networking community ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 Spine Team ... annual Reader’s Choice ‘Best of 2014’ award based on ... Northeast Tarrant County, Las Colinas & Coppell, Rockwall & ... would like to thank our patients and the residents ... Texas as LIVING magazine’s ‘Best of 2014’ in the ...
(Date:9/1/2014)... an innovative Washington State University study of deadly force ... black people. But when it came time to shoot, ... longer to pull the trigger against them than against ... the recent Journal of Experimental Criminology , grow ... disproportionate number of ethnic and racial minorities shot by ...
(Date:9/1/2014)... UWDress.com, a well-known wedding dress manufacturer and ... green bridesmaid dresses for its new and old ... company’s online category. What’s more, they are offered at ... offer is specially launched to celebrate the coming of ... have won great appreciation from worldwide clients. Now, the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:Spine Team Texas chosen in LIVING Magazine’s Reader’s Choice Awards 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:2014 Lime Green Bridesmaid Dresses Offered At UWDress.com 2
... could help keep ones mind working.The study also found those ... fat have an increased risk of cognitive impairment during middle ... eat could play a role in your risk for dementia. ... with a lower risk of dementia. Researchers in the Netherlands ...
... in the recent issue of British Medical Journal say ... suicides and suicidal attempts.// ,Depression is characterized ... activities, low levels of self-esteem and confidence, and in ... and suicide. ,Clinical depression, also known as ...
... thyroid problem may have a lower risk of developing ... have shown that one of the circulating thyroid hormones ... mammary gland cells responded to thyroid hormones , population ... thyroid hormone and breast cancer. ,In a recent ...
... recent study researchers suggest that women drink wine to keep their ... wine is good for the heart. Although much of the research ... men, it is still not clear why moderate amounts of wine ... effects of wine on women’s hearts, the alcohol habits of 102 ...
... research conducted by Northwestern University about the effects of epidural ... analgesic given at the early stages of labor does not ... in their final term were observed for the study. All ... women who were given epidural in the early stages of ...
... onset wheezing is associated with high levels of allergies, ... the longest duration of wheezing also appear to have ... later in childhood end up with the same characteristics ... involved nearly 1,500 children born on the Isle of ...
Cached Medicine News:
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Medicine Products: